The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Novel immunotherapy agents on the horizon for lung cancer
Hossein Borghaei, DO, MS, Fox Chase Cancer Center, Philadelphia, PA, talks on novel immunotherapy (IO) agents on the horizon in lung cancer, including new checkpoint inhibitors entering clinical trials, TIL therapies, CAR-T cells, vaccines and antibody-drug cojugates (ADCs). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
